Uterine Serous Carcinoma Recruiting Phase 2 Trials for Azenosertib (DB18028)

IndicationStatusPhase
DBCOND0122528 (Uterine Serous Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04814108A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous CarcinomaTreatment